Table 4.
Factors contributing to the development of AKI
| Description | All Patients | Monotherapy | Combination Therapy | P Value |
|---|---|---|---|---|
| AKI events | 295 | 105 | 190 | |
| No. of events (%) with evaluable dataa | 290 (98.3) | 104 (99.0) | 186 (97.9) | |
| Predisposing factorsb (%) | ||||
| Volume depletionc | 176 (60.7) | 59 (56.7) | 117 (62.9) | 0.30 |
| Diureticsc | 161 (55.5) | 61 (58.7) | 100 (53.8) | 0.42 |
| Acute gastrointestinal illnessc | 53 (18.3) | 14 (13.5) | 39 (21.0) | 0.11 |
| Medicationsc | 142 (49.0) | 56 (54.4) | 86 (46.2) | 0.21 |
| Iodinated radiocontrast mediac | 12 (4.1) | 5 (4.8) | 7 (3.8) | 0.67 |
| Aminoglycoside antibioticsc | 8 (2.8) | 3 (2.9) | 5 (2.7) | 0.92 |
| Vasopressorsc | 4 (1.4) | 2 (1.8) | 2 (1.0) | 0.55 |
| Urinary retentionc | 26 (9.0) | 14 (13.5) | 12 (6.5) | 0.05 |
a
Percentages calculated on the basis of total number of AKI events.
b
Totals exceed 100%, because patients may have had more than one contributing factor.
c
Percentages calculated on the basis of number of AKI events with evaluable data.